文献速递药物不良反应与药物警戒

法国药物不良反应住院的经济负担:IATROSTAT-ECO研究

Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT-ECO study.
PubMed 文献 · Br J Clin Pharmacol · 2024-10-03

本研究基于2018年法国公立医院药物警戒研究IATROSTAT,从法国公共医疗保险视角估算药物不良反应住院(ADR-HA)的经济负担。研究表明严重ADR-HA对医疗支出造成沉重负担。

要点

  • 每例ADR-HA患者平均总费用为5208±3719欧元(2018年收费标准)。
  • 费用包括住院、重症监护附加费、药品器械及3个月内门诊随访。

核心结论

  • 严重ADR-HA的经济影响对医疗支出造成沉重负担,叠加昂贵药物增加、人口老龄化和多重用药因素。

研究设计与样本

  • 基于2018年法国公立医院药物警戒研究IATROSTAT的部分经济学评价,从法国公共医疗保险视角回顾性收集法国医院出院数据库的直接医疗费用。
  • 费用计算覆盖自ADR-HA首日起3个月内的住院费、复苏/重症监护/连续监测等特定病房的每日附加费、基于医疗资源分组 tariffs 之外的药品和医疗器械,以及特定门诊咨询和其他临床技术医疗操作。
  • 采用单因素确定性敏感性分析,以2023年收费标准替代2018年收费标准评估成本因素的稳健性。

临床怎么用

  • 临床药师可参考该经济负担数据,在用药审查和ADR防范中优先关注高风险患者以减少可避免的住院费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Hospitalizations for adverse drug reactions (ADR-HA) have increased over the last decade, but the impact of ADR-HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR-HA in France. METHODS: A partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR-HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group-based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3 months as from the first day of ADR-HA). The robustness of the results was assessed using a one-way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018. RESULTS: According to the 2018 tariffs (vs. 2023), the mean total cost per patient with ADR-HA was estimated at €5208 ± €3719 (vs. €5974 ± €4232) ranging from €514 to €23 355 (vs. €618 to €27 380). The total cost for 196 patients with ADR-HA admitted to a sample of French public hospitals was estimated at €1 020 549 (vs. €1 170 960). It could be estimated at €1.3 billion at the national level. CONCLUSIONS: In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR-HA weighs heavily on healthcare spending.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Laroche ML, Tarbouriech N, Jai T, et al. Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT-ECO study. Br J Clin Pharmacol. 2024. PMID: 39363642. doi:10.1111/bcp.16266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。